Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders

Novel compounds targeting TACE, TNF-α, MMPs, and ADAMs address the need for effective inhibitors to treat inflammatory disorders by reducing cartilage degradation, offering a therapeutic solution for osteoarthritis and rheumatoid arthritis.

WO2005121130A2 Publication Date: 2005-12-22SCHERING CORP +24
9 Cites 206 Cited by

Patent Information

Application Number
PCT/US2005/019131
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2004-06-02
Filing Date
2005-06-01
Publication Date
2005-12-22

AI Technical Summary

Technical Problem

Current treatments for inflammatory disorders, such as osteoarthritis and rheumatoid arthritis, lack effective inhibitors for matrix metalloproteinases (MMPs), disintegrin and metalloproteases (ADAMs), and tumor necrosis factor alpha-converting enzyme (TACE) that can prevent the degradation of cartilage and alleviate associated pathological conditions.

Method used

Development of novel compounds with a specific structural formula that inhibit TACE, TNF-α, MMPs, and ADAMs, which can be used in pharmaceutical compositions to treat and prevent diseases associated with these enzymes, thereby reducing cartilage degradation and inflammation.

Benefits of technology

The compounds effectively inhibit the activity of TACE, TNF-α, MMPs, and ADAMs, providing therapeutic benefits in treating inflammatory disorders by reducing cartilage degradation and alleviating symptoms of osteoarthritis and rheumatoid arthritis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

This invention relates to compounds of the Formula (I) or a pharmaceutically acceptable salt, solvate or isomer thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, TNF-alpha or combinations thereof.
Need to check novelty before this filing date? Find Prior Art